Simcere Zaiming Signs Exclusive Global Licensing Agreement With Roche for SIM0660 CD79a/CD19/CD3 Tri-Specific Antibody; $75 Million Upfront Plus Up to $1.53 Billion in Milestones
Simcere Zaiming (a subsidiary of China's Simcere Pharmaceutical Group) announced Wednesday September 2, 2026 an exclusive global licensing agreement with Roche for SIM0660, a T-cell engager tri-specific antibody targeting CD79a, CD19, and CD3 for B-cell-mediated diseases. Deal terms: $75 million upfront plus up to $1.53 billion in total development, regulatory, and commercial milestone payments plus tiered royalties up to double-digits on future net sales. Roche acquires exclusive global rights to develop, manufacture, and commercialize SIM0660. The molecule combines a CD3-engaging arm with binding domains targeting the two B-cell antigens CD79a and CD19 to induce T-cell-mediated cytotoxicity while limiting cytokine release, positioned to compete with the emerging poly-specific antibody category (Amgen tarlatamab, Regeneron REGN5459, Janssen amivantamab). The transaction is the latest in a $60+ billion H1 2026 wave of China-to-multinational biotech licensing that continues to feed U.S. and European pharma pipelines.